ARIAD Pharmaceuticals (ARIA) : Traders are bullish on ARIAD Pharmaceuticals (ARIA) as it has outperformed the S&P 500 by a wide margin of 32% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 6.38%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.83% in the last 1 week, and is up 35.29% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
ARIAD Pharmaceuticals (NASDAQ:ARIA): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $9.89 and $9.84 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $10.17. The buying momentum continued till the end and the stock did not give up its gains. It closed at $10.16, notching a gain of 2.52% for the day. The total traded volume was 3,648,949 . The stock had closed at $9.91 on the previous day.
The stock has recorded a 20-day Moving Average of 23.44% and the 50-Day Moving Average is 26.18%. Ariad Pharmaceuticals Inc. is up 45.56% in the last 3-month period. Year-to-Date the stock performance stands at 62.56%.
ARIAD Pharmaceuticals (ARIA) stock is expected to deviate a maximum of $1.82 from the average target price of $10.6 for the short term period. 5 Street Experts have initiated coverage on the stock with the most promising target being $13 and the most muted being $9.
ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).